Health
Rutgers leading coronavirus therapeutic clinical trial – EurekAlert
Rutgers is leading a clinical trial assessing the combination of nitazoxanide, ribavirin and hydroxychloroquine to treat people 21 or older who are infected with…
Rutgers is leading a clinical trial assessing the combination of nitazoxanide, ribavirin and hydroxychloroquine to treat people 21 or older who are infected with SARS-CoV-2 and are asymptomatic or mildly symptomatic. The trial is being conducted with Synavir Corporation, a global health company that works with academia, industry and government to develop combination treatments for new viral infections.
The trial — called Triple Combination Antiviral Coronavirus Therapy (TriACT) — seeks to determine…
-
Business18 hours agoThis leading broker thinks the CSL share price can climb 40%
-
Business10 hours agoDicker Data rides the AI trend to double digit growth
-
Business14 hours agoThis ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
General23 hours agoDenmark summons US envoy over suspected influence operations in Greenland